EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
NCT ID: NCT04515043
Last Updated: 2021-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
6 participants
INTERVENTIONAL
2020-10-16
2020-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
NCT02054104
Vaccine Therapy for Patients With Stage IV Melanoma
NCT00052156
Vaccine Therapy for Patients With Stage III Melanoma
NCT00052130
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT02157051
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
NCT04580485
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INVAC-1
All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.
blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.
blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ability to provide written informed consent and to understand and comply with the requirements of the study.
Exclusion Criteria
2. Systolic blood pressure below 90 mm Hg
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Invectys
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luis Teixeira
Role: PRINCIPAL_INVESTIGATOR
AP-HP Paris Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Louis Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INVAC1-CT-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.